Map Key
Generic Enzyme
Generic kinase
Protein kinase
Lipid kinase
Generic phosphatase
Protein phosphatase
Lipid phosphatase
Generic phospholipase
Generic protease
Metalloprotease
G-alpha
RAS - superfamily
G beta/gamma
Regulators (GDI, GAP, GEF)
Generic channel
Ligand-gated channel
Voltage-gated channel
Transporter
Normal process
Pathological process
Positive effect
Negative effect
Unspecified effect
Technical link
Disrupts in disease
Emerges in disease
Enhances in disease
Weakens in disease
Organsim specific interaction

Generic binding protein
Receptor ligand
Cell membrane glycoprotein
Transcription factor
DNA
RNA
Compound
Inorganic ion
Predicted metabolite or user's structure
Reaction
Generic receptor
GPCR
Receptors with enzyme activity
Mitochondria
EPR
Golgi
Nucleus
Lysosome
Peroxisome
Cytoplasm
Extracellular

Normal process
Pathological process
Binding
Cleavage
Covalent modifications
Phosphorylation
Dephosphorylation
Transformation
Transport
Catalysis
Transcription regulation
MicroRNA binding
Competition
Influence on expression
Unspecified interactions
Pharmacological effect
Toxic effect
Group relation
Complex subunit
Similarity reaction
A complex or a group
Organism specific object

Immune response IL-9 signaling pathway


Log In to Post A Comment

Immune response IL-9 signaling pathway

IL-9 signaling pathway

Interleukin-9 ( IL-9 ) is a multifunctional cytokine secreted by T helper 2(Th2) lymphocytes. IL-9 exerts various effects on a variety of cell typesassociated with allergic inflammation. IL-9 stimulates the growth andproliferation of T cells, enhances the production of IgE from B cells, and promotes theproliferation and differentiation of mast cells and hematopoietic progenitors [1], [2]. Besides the role of IL-9 during immune responses, itsgrowth factor and antiapoptotic activities on multiple transformed cells suggest itspotential role in tumorigenesis [3].

IL-9 binds to the heterodimeric receptor ( IL-9 receptor ) comprising aspecific chain ( IL9R ) and gamma chain ( IL-2R gamma chain ). IL-2Rgamma chain is shared by the receptors for Interleukins IL-2, IL-4, IL-7, IL-15 andIL-21.

IL-9 receptor ligation results in auto and/or trans-phosphorylation of Januskinases 1 and 3 ( JAK1 and JAK3 ), phosphorylation of the receptor, andactivation of the pathways involved in IL-9 signaling. These pathways includeSignal transducer and activator of transcription 1, 3 and 5 ( STAT1, STAT3and STAT5 ), Insulin receptor substrate 1 and 2 ( IRS-1 and IRS-2 )/Phosphoinositide-3-kinase ( PI3K reg class IA/ PI3K cat class IA ) andExtracellular signal regulated kinases 1 and 2 ( ERK1/2 ) [3].

In response to IL-9, transcriptional activities of STAT1 andSTAT3 are more related to differentiation processes, whereas STAT5, or bothSTAT1 and STAT3, are more related to the protection against apoptosis andcell proliferation [4]. 

STAT1 and STAT3, activated by IL-9, up-regulate thetranscription of Interleukin-22 ( IL-22 ), an inducible cytokine belonging to theIL-10 family that is involved in the generation of inflammatory and allergic responses[5].

IL-9 induces the expression of three cytokine signal inhibitors, Cytokineinducible SH2-containing protein (CISH), Suppressors of cytokine signaling 2 and 3 (SOCS2 and SOCS3 ). However, only SOCS3 exerts a negative effect onIL-9 activities, such as STAT3 activation and protection against apoptosis[6], [7].

IL-9 also induces B-cell CLL/lymphoma 3 ( Bcl-3 ) transcription bySTAT1 and STAT3 in T cells and mast cells. Bcl-3 expression isfollowed by an increase in the DNA binding of Nuclear factor-kappa B p50 homodimers (NF-kB p50/p50 ) that can efficiently compete with NF-kB p65/p50 heterodimers (NF-kB p50/p65 ) for the sites of NF-kB DNA binding [8]. Tumornecrosis factor alpha ( TNF-alpha ), a proinflammatory cytokine, induces NF-kBp50/p65 transcriptional activity via Tumor necrosis factor receptor superfamilymember 1A ( TNF-R1 )/ TNFRSF1A-associated via death domain ( TRADD )/ TNFreceptor-associated factor 2 ( TRAF2 )/ Mitogen-activated protein kinase kinasekinase 14 ( NIK(MAP3K14 )/ NF-kB inhibitor kinase complex ( IKK (cat) )/NF-kB inhibitor ( I-kB ) signaling pathway, leading to the expression of NF-kBp50/p65 target genes [9], [10]. IL-9 via Bcl-3expression specifically down-regulates a particular set of genes induced by NF-kBp50/p65 in response to TNF-alpha [8].

IL-9 can induce the phosphorylation of ectopically expressed IRS-1 in Tcells and of endogenous IRS-2 in other hematopoietic cells. After tyrosinephosphorylation, IRS-1 and IRS-2 interact with SH2-containing signalingproteins, such as PI3K reg class IA, SHC transforming protein 1 ( Shc )and Growth factor receptor-bound protein 2 ( GRB2 ) [3].

Positioned downstream of the PI3K reg class IA/ PI3K cat class IAsignaling, the v-Akt murine thymoma viral oncogene homolog (AKT(PKB)) does not seem to bethe main effector of IL-9 -activated IRS-1 and IRS-2 [11], [12].

A pathway that occurs downstream of Shc/ GRB2 signaling involvesstimulation of Son of sevenless homologs ( SOS )/ v-Ha-ras Harvey rat sarcomaviral oncogene homolog ( H-Ras )/ v-Raf-1 murine leukemia viral oncogene homolog 1( c-Raf-1 )/ Mitogen-activated protein kinase kinase 1 and 2 ( MEK1 andMEK2 )/ ERK1/2/ Ribosomal protein S6 kinase 90kDa polypeptide 1 (p90RSK1 ). This pathway leads to growth stimulation of hematopoietic cell lines[13], [3].